KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bausch Health Companies (BHC) Other financing activities (2016 - 2025)

Bausch Health Companies' Other financing activities history spans 16 years, with the latest figure at -$48.0 million for Q4 2025.

  • For Q4 2025, Other financing activities fell 2300.0% year-over-year to -$48.0 million; the TTM value through Dec 2025 reached -$10.0 million, up 9.09%, while the annual FY2025 figure was -$10.0 million, 9.09% up from the prior year.
  • Other financing activities for Q4 2025 was -$48.0 million at Bausch Health Companies, down from $46.0 million in the prior quarter.
  • Across five years, Other financing activities topped out at $46.0 million in Q3 2025 and bottomed at -$48.0 million in Q4 2025.
  • The 5-year median for Other financing activities is $1.0 million (2022), against an average of $777777.8.
  • The largest annual shift saw Other financing activities surged 4500.0% in 2023 before it tumbled 2300.0% in 2025.
  • A 5-year view of Other financing activities shows it stood at -$38.0 million in 2021, then surged by 97.37% to -$1.0 million in 2022, then soared by 4500.0% to $44.0 million in 2023, then tumbled by 104.55% to -$2.0 million in 2024, then crashed by 2300.0% to -$48.0 million in 2025.
  • Per Business Quant, the three most recent readings for BHC's Other financing activities are -$48.0 million (Q4 2025), $46.0 million (Q3 2025), and -$13.0 million (Q2 2025).